Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Wexler

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
Journal of the American College of Cardiology|June 13, 2001
The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled studyD S Silverberg, D Wexler, D Sheps, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|December 26, 2006
Glutaric aciduria type 1: clinical, biochemical and molecular findings in patients from IsraelStanley H Korman, Cornelis Jakobs, Patricia S Darmin, et al.
Neurology|December 31, 1997
Outcome of pyruvate dehydrogenase deficiency treated with ketogenic diets. Studies in patients with identical mutationsI D Wexler, S G Hemalatha, J McConnell, et al.
Clinical Nephrology|September 14, 2002
The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalizationD S Silverberg, D Wexler, M Blum, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2006
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infectionA J Ullmann, O A Cornely, A Burchardt, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|March 13, 2002
Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseasesD S Silverberg, D Wexler, M Blum, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1988
Heterogeneous expression of protein and mRNA in pyruvate dehydrogenase deficiencyI D Wexler, D S Kerr, L Ho, et al.
Human Mutation|January 1, 1992
Mutations and polymorphisms in the pyruvate dehydrogenase E1 alpha geneH H Dahl, G K Brown, R M Brown, et al.
Biochimica Et Biophysica Acta|October 21, 1994
Primary amino acid sequence and structure of human pyruvate carboxylaseI D Wexler, Y Du, M V Lisgaris, et al.
Journal of the American College of Cardiology|June 7, 2000
The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizationsD S Silverberg, D Wexler, M Blum, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
Journal of the American College of Cardiology|June 13, 2001
The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled studyD S Silverberg, D Wexler, D Sheps, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|December 26, 2006
Glutaric aciduria type 1: clinical, biochemical and molecular findings in patients from IsraelStanley H Korman, Cornelis Jakobs, Patricia S Darmin, et al.
Neurology|December 31, 1997
Outcome of pyruvate dehydrogenase deficiency treated with ketogenic diets. Studies in patients with identical mutationsI D Wexler, S G Hemalatha, J McConnell, et al.
Clinical Nephrology|September 14, 2002
The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalizationD S Silverberg, D Wexler, M Blum, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2006
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infectionA J Ullmann, O A Cornely, A Burchardt, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|March 13, 2002
Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseasesD S Silverberg, D Wexler, M Blum, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1988
Heterogeneous expression of protein and mRNA in pyruvate dehydrogenase deficiencyI D Wexler, D S Kerr, L Ho, et al.
Human Mutation|January 1, 1992
Mutations and polymorphisms in the pyruvate dehydrogenase E1 alpha geneH H Dahl, G K Brown, R M Brown, et al.
Biochimica Et Biophysica Acta|October 21, 1994
Primary amino acid sequence and structure of human pyruvate carboxylaseI D Wexler, Y Du, M V Lisgaris, et al.
Journal of the American College of Cardiology|June 7, 2000
The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizationsD S Silverberg, D Wexler, M Blum, et al.
Pageof 12